161 related articles for article (PubMed ID: 38792050)
1. Identification of New Substrates and Inhibitors of Human CYP2A7.
Ashraf RA; Liu S; Wolf CA; Wolber G; Bureik M
Molecules; 2024 May; 29(10):. PubMed ID: 38792050
[TBL] [Abstract][Full Text] [Related]
2. CYP2A6: genetics, structure, regulation, and function.
Raunio H; Rahnasto-Rilla M
Drug Metabol Drug Interact; 2012 May; 27(2):73-88. PubMed ID: 22706231
[TBL] [Abstract][Full Text] [Related]
3. Characterization of a novel CYP2A7/CYP2A6 hybrid allele (CYP2A6*12) that causes reduced CYP2A6 activity.
Oscarson M; McLellan RA; Asp V; Ledesma M; Bernal Ruiz ML; Sinues B; Rautio A; Ingelman-Sundberg M
Hum Mutat; 2002 Oct; 20(4):275-83. PubMed ID: 12325023
[TBL] [Abstract][Full Text] [Related]
4. CYP2A7 polymorphic alleles confound the genotyping of CYP2A6*4A allele.
Fukami T; Nakajima M; Sakai H; McLeod HL; Yokoi T
Pharmacogenomics J; 2006; 6(6):401-12. PubMed ID: 16636685
[TBL] [Abstract][Full Text] [Related]
5. Characterization of novel CYP2A6 polymorphic alleles (CYP2A6*18 and CYP2A6*19) that affect enzymatic activity.
Fukami T; Nakajima M; Higashi E; Yamanaka H; Sakai H; McLeod HL; Yokoi T
Drug Metab Dispos; 2005 Aug; 33(8):1202-10. PubMed ID: 15900015
[TBL] [Abstract][Full Text] [Related]
6. In Silico Structural, Virtual Screening and Docking Studies of Human Cytochrome P450 2A7 Protein.
Lodhi SS; Farmer R; Jaiswal YK; Wadhwa G
Interdiscip Sci; 2015 Jun; 7(2):129-35. PubMed ID: 26239541
[TBL] [Abstract][Full Text] [Related]
7. Determination of coumarin metabolism in Turkish population.
Cok I; Aygün Kocabaş N; Cholerton S; Karakaya AE; Sardaş S
Hum Exp Toxicol; 2001 Apr; 20(4):179-84. PubMed ID: 11393269
[TBL] [Abstract][Full Text] [Related]
8. Diversity of selective environmental substrates for human cytochrome P450 2A6: alkoxyethers, nicotine, coumarin, N-nitrosodiethylamine, and N-nitrosobenzylmethylamine.
Le Gal A; Dréano Y; Lucas D; Berthou F
Toxicol Lett; 2003 Sep; 144(1):77-91. PubMed ID: 12919726
[TBL] [Abstract][Full Text] [Related]
9. 3'-UTR polymorphism in the human CYP2A6 gene affects mRNA stability and enzyme expression.
Wang J; Pitarque M; Ingelman-Sundberg M
Biochem Biophys Res Commun; 2006 Feb; 340(2):491-7. PubMed ID: 16378601
[TBL] [Abstract][Full Text] [Related]
10. Identification of new probe substrates for human CYP20A1.
Durairaj P; Fan L; Sharma SS; Jie Z; Bureik M
Biol Chem; 2020 Feb; 401(3):361-365. PubMed ID: 31655790
[TBL] [Abstract][Full Text] [Related]
11. CYP2A7 pseudogene transcript affects CYP2A6 expression in human liver by acting as a decoy for miR-126.
Nakano M; Fukushima Y; Yokota S; Fukami T; Takamiya M; Aoki Y; Yokoi T; Nakajima M
Drug Metab Dispos; 2015 May; 43(5):703-12. PubMed ID: 25710939
[TBL] [Abstract][Full Text] [Related]
12. Expression and alternative splicing of the cytochrome P-450 CYP2A7.
Ding S; Lake BG; Friedberg T; Wolf CR
Biochem J; 1995 Feb; 306 ( Pt 1)(Pt 1):161-6. PubMed ID: 7864805
[TBL] [Abstract][Full Text] [Related]
13. Homologous unequal cross-over within the human CYP2A gene cluster as a mechanism for the deletion of the entire CYP2A6 gene associated with the poor metabolizer phenotype.
Nunoya K; Yokoi T; Takahashi Y; Kimura K; Kinoshita M; Kamataki T
J Biochem; 1999 Aug; 126(2):402-7. PubMed ID: 10423536
[TBL] [Abstract][Full Text] [Related]
14. A genetic polymorphism in coumarin 7-hydroxylation: sequence of the human CYP2A genes and identification of variant CYP2A6 alleles.
Fernandez-Salguero P; Hoffman SM; Cholerton S; Mohrenweiser H; Raunio H; Rautio A; Pelkonen O; Huang JD; Evans WE; Idle JR
Am J Hum Genet; 1995 Sep; 57(3):651-60. PubMed ID: 7668294
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of coumarin 7-hydroxylase activity in human liver microsomes.
Draper AJ; Madan A; Parkinson A
Arch Biochem Biophys; 1997 May; 341(1):47-61. PubMed ID: 9143352
[TBL] [Abstract][Full Text] [Related]
16. Structure, function, regulation and polymorphism of human cytochrome P450 2A6.
Di YM; Chow VD; Yang LP; Zhou SF
Curr Drug Metab; 2009 Sep; 10(7):754-80. PubMed ID: 19702528
[TBL] [Abstract][Full Text] [Related]
17. Quantitative structure-activity relationship analysis of inhibitors of the nicotine metabolizing CYP2A6 enzyme.
Rahnasto M; Raunio H; Poso A; Wittekindt C; Juvonen RO
J Med Chem; 2005 Jan; 48(2):440-9. PubMed ID: 15658857
[TBL] [Abstract][Full Text] [Related]
18. Functional characterization of allelic variants of polymorphic human cytochrome P450 2A6 (CYP2A6*5, *7, *8, *18, *19, and *35).
Han S; Choi S; Chun YJ; Yun CH; Lee CH; Shin HJ; Na HS; Chung MW; Kim D
Biol Pharm Bull; 2012; 35(3):394-9. PubMed ID: 22382327
[TBL] [Abstract][Full Text] [Related]
19. Evaluation of inhibition selectivity for human cytochrome P450 2A enzymes.
Stephens ES; Walsh AA; Scott EE
Drug Metab Dispos; 2012 Sep; 40(9):1797-802. PubMed ID: 22696418
[TBL] [Abstract][Full Text] [Related]
20. A novel CYP2A6*20 allele found in African-American population produces a truncated protein lacking enzymatic activity.
Fukami T; Nakajima M; Higashi E; Yamanaka H; McLeod HL; Yokoi T
Biochem Pharmacol; 2005 Sep; 70(5):801-8. PubMed ID: 15993850
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
